Table 3.
Myeloablative Conditioning Regimen in Patients With SCD.
| No. | Age range (years) | Graft source (N) |
Donor (N) |
Conditioning regimen | GvHD prophylaxis | Acute GvHD (grade II–IV) | Chronic GvHD | OS % | EFS % | |
|---|---|---|---|---|---|---|---|---|---|---|
| Bernaudin et al. 24 | 87 | 2–22 | BM: 74 PB:1 UCB: 12 |
MRD | MAC: BU + CY ± ATG |
CSA± MTX | 20% | Limited: 11% Extensive: 2.4% |
6 years: 93.1% |
6 years: 86.1% |
| Panepinto et al. 25 | 67 | 2–27 | BM: 54 PB:9 UCB: 4 |
MRD | MAC: BU+CY |
CSA+ MTX Tacrolimus T cell depletion Non |
10% | 22% Limited:9 patients Extensive: 3 patients |
5 years: 97% |
5 years: 85% |
| Strocchio et al. 26 | 30 | 1.7–18.8 | BM: 22 PB:1 UCB: 4 BM + UCB: 3 |
MRD: 24 MUD: 6 |
MAC: BU+Thio+Flu Treo+Thio+Flu ± ATG |
CSA± MTX | 7% in the Bu- and 0% in the Treo-group |
7% in the Bu- and 0% in the Treo-group | 100% | 5-years: 93% MRD: 96% MUD: 83% |
| Krishnamurti et al. 27 | 22 | 17–36 | BM | MRD: 17 MUD: 5 |
MAC: BU+ Flu+ATG |
CNI+MTX | 18% | 27% | 1 year: 91% MRD: 94% MUD: 80% |
1 year: 86% MRD: 94% MUD: 60% |
| Kogel et al. 28 | 25 | 1–21 | BM: 21 PB: 4 |
MRD: 17 MUD: 8 |
MAC: BU+CY Flu+Thio+Treo Flu+Thio+Alk |
CSA + MTX CSA + MMF CSA Tacrolimus+MTX CSA + MMF+MTX |
grade I–II: 8 patients | No | 100% | 88% |
| Dedeken et al. 29 | 50 | 1.7–15.3 | BM: 39 PB:1 UCB: 3 BM + UCB: 7 |
MRD | MAC: BU+CY± ATG |
CSA + MTX CSA CSA+MMF |
grade I –II: 12% grade III–IV: 10% |
Mild in 10 patients | 8 years: 94.1% | 8 years: 85.6% |
| Bernaudin et al. 30 | 234 | 2.2–28.9 | BM: 195 PB:1 UCB: 30 BM + UCB: 8 |
MRD | MAC: BU+CY± ATG |
CSA± MTX | 20.1% | 10.5% | 97% | 93.9% |
Alk: alkeran(melphalan); ATG: anti-thymocyte globulin BM: bone marrow; BU: busulfan; CNI: calcineurin inhibitor; CSA: cyclosporine; CY: cyclophosphamide; EFS: event-free survival; Flu: fludarabine; GvHD: graft versus host disease; MAC: myeloablative conditioning; MMF: mycophenolate mofetil; MRD: matched related donor; MUD: matched unrelated donor; MTX: methotrexate; OS: overall survival; PB: peripheral blood; Thio: thiotepa; Treo: treosulfan; UCB: umblical cord blood.